Best Genomics Companies in New Jersey, United States
The 39 best Genomics companies in New Jersey, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: VaxInnate.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in New Jersey
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VaxInnate Vaccines for infectious diseases, including seasonal and pandemic flu, dengue and Clostridium difficile… | $129M | 120 mo ago | Deadpooled | — | 2002 | — | 130 patents Recombinant protein vaccine antigens and adjuvant formulations for infectious disease immunization | — |
| 2 | Interpace Diagnostics Molecular diagnostics and pathology services for early cancer diagnosis and treatment | $27M | 85 mo ago | Public | — | 2013 | — | — | — |
| 3 | DiamiR Developer of minimally invasive diagnostic tests | $22M | 16 mo ago | Funding Raised | — | 2009 | — | 55 patents miRNA biomarker assays for diagnosing and monitoring neurodegenerative diseases | — |
| 4 | GenScript Provider of reagents and instruments for life sciences research | $15M | 206 mo ago | Public | — | 2002 | Cart FunctionalityZohoPHP+25 | 11 patents Recombinant DNA cloning, protein engineering, electrophoresis devices, and immunoassay technologies. | — |
| 5 | Cancer Genetics Developer of cancer diagnostic solutions for personalized treatment | $10M | 67 mo ago | Public | John Roberts CEO | 1999 | — | 35 patents Molecular diagnostic microarrays for cancer classification, prognosis, and HPV-associated tumor detection. | — |
| 6 | Enterix Easy at-home colorectal cancer screening using toilet bowl water | $8M | 301 mo ago | Acquired | Robert Max Mawhinney Co-Founder | 1997 | WordPressMySQLPHP+18 | 12 patents Portable chemical analyte detection and sampling devices for point‑of‑care testing | — |
| 7 | Genomic Prediction Offers genomics tests for IVF health outcomes | $4M | 91 mo ago | Deadpooled | Laurent Christian Asker Melchior Tellier CEO | 2017 | — | — | — |
| 8 | CytoSite Bio Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $3M | 71 mo ago | Series A | Benjamin Larimer Co-Founder | 2016 | — | — | — |
| 9 | Oncospire Genomics Developer of NGS gene panels for oncology | $1M | 158 mo ago | Deadpooled | Panna Sharma CEO & President | 2013 | — | — | — |
| 10 | Bar Harbor BioTech Developer of molecular biology products and services for life science research and clinical medicine | $995K | 137 mo ago | Deadpooled | — | 2006 | — | — | — |
| 11 | Generation Biotech Provider of targeted capture technology for DNA sequencing | $851K | 83 mo ago | Funding Raised | Johannes Dapprich CEO | 2000 | — | — | — |
| 12 | Medical Laboratory Diagnostic Provider of in-person and online religious services | $778K | 193 mo ago | Funding Raised | — | 1997 | PHPSplidejQuery+6 | — | — |
| 13 | Genewiz Provider of a wide range of genomic services for the life sciences industry | $143K | 75 mo ago | Acquired | Amy Liao Co-Founder & CEO | 1999 | WordPressMySQLPHP+27 | 6 patents High‑throughput DNA sequencing, microbial identification kits, and ADP quantification assays. | — |
Top 12 Genomics companies in New Jersey
#1
Funding Raised · Monmouth Junction, New Jersey · founded 2009 · 13 employees$21.8Mraised▾
Developer of minimally invasive diagnostic tests. It has developed a proprietary targeted approach for early detection and monitoring of neurodegenerative diseases based on quantitative analysis of brain-enriched microRNA pairs in plasma. The company has collaborated with Janssen Neuroscience to investigate how DiamiR technology can be used in the context of clinical development of a therapeutic agent for the treatment of neurodegenerative disease. Its lead product CogniMir is aimed at early detection of circulating miRNAs for the early detection of Alzheimer's disease.
- May 2025Grant (prize money)$9.5M
- Sep 2020Grant (prize money)$609.5K
- Sep 2019Grant (prize money)$345K
- Jun 2016Grant (prize money)$224.6K
#2
Deadpooled · Cranbury, New Jersey · founded 2002 · 62 employees$128.7Mraised▾
VaxInnate Corporation develops vaccines based on the technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. The company’s technology platform is based on proprietary toll-like receptor technology, which potentiates the immune response. Its vaccines focus on infectious diseases, including seasonal and pandemic influenza, Clostridium difficile, and dengue.
- Aug 2016Grant (prize money)$110K
- Sep 2015Series D$3.2M
- Oct 2014Series D$6M
- Jan 2014Grant (prize money)$2.1M
#3
Public · Rutherford, New Jersey · founded 1999 · 110 employees$9.8Mraised▾
Developer of cancer diagnostic solutions for personalized treatment. The company is offering products and services that enable genetic cancer diagnostics and personalized treatments. Its proprietary tests and reference lab provide genomic information about patients and help physicians to diagnose and monitor cancer treatment.
- Jan 2021Post IPO$10M
- Jul 2018Post IPO$2.6M
- Dec 2017Grant (prize money)$1.1M
- Dec 2017Post IPO$7M
#4
Public · Parsippany Troy Hills, New Jersey · founded 2013 · 120 employees$27Mraised▾
Molecular diagnostics and pathology services for early cancer diagnosis and treatment. A life sciences company focused on providing complex molecular analysis. They offer clinically beneficial molecular diagnostic tests and pathology services, contributing to evidence-based approaches in healthcare. The company is dedicated to bringing insights to life through its diagnostic solutions. They operate in the life sciences industry, providing services for early diagnosis and treatment of cancer. Their offerings support physicians and patients in making informed decisions. They are committed to advancing the field of molecular diagnostics and pathology.
- Jul 2019Post IPO$27M
#5
Public · Piscataway, New Jersey · founded 2002 · 5260 employees$15Mraised▾
Provider of reagents and instruments for life sciences research. It provides a portfolio of services that include Bio-reagent, Bio-assay, lead optimization, and antibody drug development. Along with this, the company focuses on CRISPR reagents and reagents for CRISPR/CAS9 genome editing in particular. Additionally, the product line comprises several bioinformatics tools as well, such as the Molecular biology tool, Peptide tool, and protein tool.
- Jun 2009Series A$15M
#6
Series A · New Jersey · founded 2016$3Mraised▾
Developer of immunotherapies for the treatment of cancer and autoimmune diseases. The company develops precision PET imaging agents targeting Granzyme B to assess immunotherapy response in cancer patients. The company focuses on non-invasive imaging of T cell and NK cell activation for early treatment evaluation.
- Sep 2020Series A$3M
- Sep 2018Grant (prize money)$1.8M
- Aug 2018Series A$4.4M
- Dec 2017Seed$10.8K
#7
Acquired · Edison, New Jersey · founded 1997 · 54 employees$7.5Mraised▾
Easy at-home colorectal cancer screening using toilet bowl water. This innovative company provides a simple, private, and effective way to screen for colorectal cancer from the comfort of your own home. Their Fecal Immunochemical Test (FIT) eliminates the need to handle stool, using a water-based sample collected with a brush. The process involves receiving a test kit, collecting the sample, and mailing it back for analysis. Results are typically available through your healthcare provider within a couple of weeks, emphasizing the importance of follow-up for positive results. This preventative screening solution aims to detect colorectal cancer early, potentially saving lives. They offer resources, support, and contact information for healthcare professionals and individuals seeking to buy the test. This is a B2C healthcare solution.
- Jul 2001Series A$7.5M
#8
Deadpooled · North Brunswick, New Jersey · founded 2017 · 34 employees$4.5Mraised▾
Genomic Prediction is engaged in providing services in evaluating genetic risk due to chromosomal abnormality (ploidy), single-gene mutations, and polygenic diseases. The product portfolio of the company comprises of expanded pre-implantation genomic testing which screens for single-gene disorders, such as Cystic Fibrosis, Thalassemia, BRCA, Sickle Cell Anemia, and Gaucher Disease. Additionally, the company has developed novel single-step library preparation method for next-generation sequencing of embryo biopsies and fully automated cloud-based analysis of sequencing results.
- Jan 2019Series A$4.5M
#9
Funding Raised · Hamilton Township, New Jersey · founded 2000$851.5Kraised▾
Provider of targeted capture technology for DNA sequencing. The company is commercializing its proprietary methodology for targeted capture, enrichment, and sequencing of large genomic regions based either on the region-specific capture or the haplotype-specific capture of DNA fragments covering regions exceeding 20kb.
- Sep 2019Grant (prize money)$225K
- Apr 2017Grant (prize money)$331.3K
- Sep 2012Grant (prize money)$295.2K
#10
Deadpooled · Trenton, New Jersey · founded 2006 · 7 employees$995.2Kraised▾
Bar Harbor BioTechnology is developing molecular biology products and services that advance life science research and clinical medicine. The company offers polymerase chain reaction-based laboratory products and computational tools for molecular profiling at the levels of RNA-based gene expression and DNA-based gene quantification. It seems to be out of business.
- Mar 2015Seed$180K
- May 2011Seed$280K
- May 2010Seed$25K
- Sep 2006Seed$11.2K
#11
Deadpooled · Rutherford, New Jersey · founded 2013 · 86 employees$1Mraised▾
Developer of NGS gene panels for oncology. The company has three panels include a test for the early diagnosis of lung cancer, a test for predicting the risk of developing multiple myeloma in patients diagnosed with monoclonal gammopathy of undetermined significance (MGUS), and a test to predict patient outcome in follicular lymphoma.
- 2013Grant (prize money)$1M
#12
Funding Raised · Trenton, New Jersey · founded 1997 · 539 employees$778.4Kraised▾
Provider of in-person and online religious services. It offers various ministries for different age groups and life stages, including children, youth, young adults, men, women, and marriage groups. The organization provides opportunities for community engagement through events, small groups, and volunteer programs. It also offers online resources such as live messages, notes, and playlists. Additionally, it facilitates spiritual growth through Bible studies and other faith-based initiatives. The services aim to foster spiritual development and community building within a faith-based context.
- Aug 2010Grant (prize money)$389.2K
- Jul 2010Grant (prize money)$389.2K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Genomsys7
- Baluch Mohamed Khoso7
- Microsoft6
- Contamination Source Identificat5
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.